Multiple myeloma is generally considered incurable rather than imminently terminal, and the distinction matters enormously. Most oncologists will tell a newly diagnosed patient that myeloma cannot be completely eliminated, but many patients now live for years or even more than a decade with treatment. In one study, roughly 85 percent of patients said their oncologist told them the cancer was incurable, yet only about 31 percent described themselves as terminally ill. That gap reflects a real medical reality: myeloma behaves less like a disease with a single countdown clock and more like a chronic condition punctuated by relapses, each of which can often be treated again.
What “Incurable but Treatable” Actually Means
When doctors say myeloma is incurable, they mean that with current therapies, most patients will eventually relapse. The cancer can be driven into remission, sometimes deep remission where no detectable disease remains, but traces of abnormal plasma cells tend to persist. Those cells can re-emerge months or years later, requiring a new round of treatment. This cycle of remission and relapse is what separates myeloma from cancers that can be “cured” in the traditional sense, where the disease is gone for good after treatment ends.
That said, calling myeloma terminal in the way most people understand the word is misleading. Terminal typically implies a short and predictable timeline toward death, with little that medicine can do. Myeloma does not fit that description for most patients diagnosed today. Median survival has been climbing steadily, and many patients go through multiple lines of effective therapy over the course of their disease. The phrase “incurable but treatable” is the one you’ll hear most often from hematologists, and while it can feel like a contradiction, it accurately captures where things stand.
How Long People Actually Live With Myeloma Now
Survival statistics have shifted dramatically over the past two decades. A real-world study tracking patients at a single hospital found that median survival rose from about 51 months for those diagnosed between 2000 and 2007 to about 72 months for those diagnosed between 2008 and 2015. For patients diagnosed between 2016 and 2022, the median had not yet been reached at the time of analysis, meaning more than half were still alive.1PubMed Central. Evolution of Survival in Patients with Multiple Myeloma over Two Decades: A Real-World Experience from a Medium-Level Hospital That upward trend tracks closely with the introduction of newer drug classes. Patients whose first-line treatment included proteasome inhibitors had a median survival around 79 months, while those who received immunomodulatory drugs reached about 99 months. For the newest class of drugs, anti-CD38 monoclonal antibodies, the median had not been reached at all.1PubMed Central. Evolution of Survival in Patients with Multiple Myeloma over Two Decades: A Real-World Experience from a Medium-Level Hospital
These are medians, which means half of patients in each group lived longer. For patients diagnosed at an early stage with favorable biology, survival well beyond ten years is realistic. But the range is wide. Someone diagnosed with advanced-stage disease and high-risk genetic features faces a much shorter timeline. Averages obscure as much as they reveal here.
Staging and Why Outcomes Vary So Much
Myeloma is staged using the Revised International Staging System, which combines blood markers with genetic testing of the tumor cells. The system sorts patients into three groups, and the survival differences between them are stark. In a large international study, five-year overall survival was about 82 percent for Stage I, 62 percent for Stage II, and 40 percent for Stage III. Median survival for Stage III was roughly 43 months, while median survival for Stage I had not been reached at the time of analysis, meaning most Stage I patients were still alive after nearly four years of follow-up.2Journal of Clinical Oncology. Revised International Staging System for Multiple Myeloma: A Report From the International Myeloma Working Group
The genetic abnormalities in myeloma cells matter a great deal. Certain chromosomal changes, like deletion of part of chromosome 17 or specific translocations, mark a disease that tends to be more aggressive and less responsive to standard treatment. In one retrospective study, about 16 percent of patients had high-risk genetic features.3PubMed Central. Cytogenetics and Revised International Staging System (R-ISS): Risk Stratification in Multiple myeloma – A Retrospective Study in Indian Population Those patients generally need more intensive therapy and tend to relapse sooner, though newer treatments are beginning to narrow that gap.
Treatments That Changed the Landscape
The reason myeloma outcomes look so different today compared to a generation ago comes down to an expanding toolkit of drugs. Before the early 2000s, treatment options were largely limited to conventional chemotherapy. The arrival of three drug classes transformed the disease: thalidomide and its successors (immunomodulatory drugs), bortezomib and related proteasome inhibitors, and most recently monoclonal antibodies like daratumumab.4PubMed Central. Treatment of multiple myeloma: a comprehensive review
Daratumumab in particular has reshaped first-line treatment. In the MAIA trial, which studied transplant-ineligible newly diagnosed patients, adding daratumumab to a standard two-drug backbone cut the risk of progression or death by about half. At nearly five years of follow-up, median overall survival had not been reached in the daratumumab group.5The Lancet Oncology. Daratumumab, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma: overall survival results of the phase 3 MAIA trial In the ALCYONE trial, which tested daratumumab in combination with a different backbone regimen, the three-year survival rate was 78 percent in the daratumumab group versus 68 percent without it.6The Lancet. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial For patients who relapsed after prior treatment, the POLLUX trial showed daratumumab extended median survival from about 52 months to nearly 68 months.7PubMed Central. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Stem Cell Transplant Still Plays a Major Role
For patients who are young and fit enough to tolerate it, high-dose chemotherapy followed by autologous stem cell transplant remains a standard part of treatment. A meta-analysis of trials found that transplant improved overall survival compared with drug therapy alone.8PubMed Central. Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis Transplant essentially resets the bone marrow environment and, when followed by maintenance therapy, provides longer periods without active disease.9PubMed Central. Role of Stem Cell Transplantation in Multiple Myeloma
Even older patients can benefit. In a study of patients aged 65 and older, those who received a transplant had a median overall survival of about 80 months compared with 40 months for similar patients who did not, a near doubling.10PubMed. Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life The gap was even more pronounced in high-risk patients, where transplant extended median survival from 38 months to nearly 78 months.10PubMed. Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life That said, fitness for transplant is assessed individually, and frail patients or those with significant other health problems may do better with adjusted drug regimens. Triplet drug combinations work well in older but non-frail patients, while dose-reduced versions of those combinations are recommended for frail patients.11PubMed. Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma
Deep Remission and the Question of Functional Cure
One of the more hopeful developments in myeloma is the concept of minimal residual disease, or MRD. This refers to testing for tiny traces of myeloma cells that survive treatment, even when standard tests show no evidence of disease. Patients who test MRD-negative after treatment do significantly better than those who still have detectable disease. A meta-analysis found that MRD-negative patients had a median progression-free survival of 54 months compared to 26 months for MRD-positive patients, and median overall survival of 98 months versus 82 months.12JAMA Oncology. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis
A small but growing number of patients who achieve sustained MRD-negative status may eventually be considered functionally cured, though the field is cautious about using that word. MRD status after treatment is now considered an independent predictor of how well someone will do, regardless of which drugs were used to get there.13PubMed Central. Minimal residual disease in multiple myeloma: current status Newer therapies, including CAR T-cell therapy for relapsed disease, are pushing MRD-negative rates higher. In an early CAR T-cell trial targeting a protein called BCMA, 85 percent of heavily pretreated patients responded, and all evaluable responders who achieved at least a partial response tested MRD-negative.14PubMed Central. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma These responses were not always durable in that trial, but the technology is still being refined, and later-generation products have shown improved results.
Precursor Conditions and When the Clock Starts
Not everyone who develops myeloma goes from healthy to a cancer diagnosis overnight. Most cases are preceded by a condition called MGUS (monoclonal gammopathy of undetermined significance), in which abnormal proteins are present in the blood but no damage has occurred. MGUS progresses to active myeloma at a rate of about 1 percent per year, and only about 20 percent of people with MGUS ever develop myeloma at all.15International Myeloma Foundation. MGUS, Smoldering Myeloma & Multiple Myeloma: Differences
Between MGUS and active myeloma sits smoldering myeloma, a higher-risk intermediate state. The progression rate from smoldering myeloma is about 10 percent per year, though it is not uniform across patients.16PubMed. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology Some patients with smoldering myeloma have features that put them at very high risk, with roughly an 80 percent chance of progressing to symptomatic disease within two years. Those patients are now reclassified as having active myeloma requiring treatment, even if they do not yet have symptoms like bone damage or kidney failure.17PubMed. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma The existence of this slow precursor pipeline is another reason the “terminal illness” framing can be misleading. Some people live with precursor states for decades without ever needing treatment.
Bone Disease and What Drives Day-to-Day Suffering
Regardless of how long someone lives with myeloma, the disease can exact a heavy toll on quality of life. Bone disease is the most common and often most debilitating complication. Myeloma cells disrupt the normal cycle of bone repair, leading to bone pain, weakened bones, fractures, and sometimes spinal cord compression.18PubMed Central. Consensus on Surgical Management of Myeloma Bone Disease The International Myeloma Working Group recommends bisphosphonate drugs for all myeloma patients starting first-line treatment, regardless of whether bone lesions are visible on imaging, because preventive treatment reduces the chance of fractures and other skeletal complications.19PubMed Central. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease
Fractures are not just painful. They are independently associated with shorter survival. A large population-based study found that patients who had a fracture at diagnosis faced a roughly 28 percent higher risk of death compared with those who did not, and the risk was doubled for fractures occurring after diagnosis.20PubMed Central. Fractures and survival in multiple myeloma: results from a population-based study Kidney failure is another serious complication, caused either by toxic antibody fragments damaging the kidneys or by high blood calcium levels.21PubMed Central. Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management Managing these complications is just as important as treating the myeloma itself, and they are a big part of what determines whether a patient’s remaining years are comfortable ones.
The Psychological Weight of an “Incurable” Diagnosis
Being told you have an incurable cancer is psychologically devastating even when the expected survival is measured in years. In a study of 180 myeloma patients, about 24 percent had clinically significant depression, about 24 percent had significant anxiety, and about 24 percent had symptoms of post-traumatic stress disorder.22PubMed. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma There is also a striking disconnect in how patients process the information they receive. In the same study, most patients reported that their oncologist told them the cancer was incurable, but only about 42 percent actually believed it was incurable, and fewer than a third described themselves as terminally ill.22PubMed. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma
Research on how myeloma patients cope with prognosis suggests that acceptance is an adaptive strategy linked to less psychological distress, but that both hope and uncertainty run high in this patient population.23PubMed. Perspectives of patients with multiple myeloma on accepting their prognosis-A qualitative interview study A scoping review found that many patients and caregivers retained a belief in cure even after being told it was not achievable, and that many felt they did not receive enough prognostic information from their care team.24PubMed. Patient and caregiver understanding of multiple myeloma: A scoping review The tension between medical reality and personal hope is more pronounced in myeloma than in many other cancers, precisely because the disease can be managed for so long. When someone is still living an active life five years after diagnosis, the word “terminal” can feel absurd even if it is technically applicable in the long run.
Disability Recognition and Practical Consequences
Whether myeloma is classified as terminal has real-world consequences beyond medicine. In the United States, the Social Security Administration maintains a Compassionate Allowances list, which fast-tracks disability benefits for conditions considered so severe that the claim is essentially automatic. Several blood cancers are on that list, including acute myeloid leukemia and relapsed non-Hodgkin lymphoma. Multiple myeloma is not, despite what researchers have described as comparable disease severity, treatment toxicity, and functional impairment.25PubMed. A Call for Compassion: How You Can Help Get Multiple Myeloma Added to the Social Security Administration’s Compassionate Allowances List This means myeloma patients seeking disability benefits often face a longer and more arduous application process.
The financial burden of living with myeloma is substantial. Because treatment often continues for years, the cumulative cost of drugs, clinic visits, and monitoring adds up. Researchers have identified two distinct forms of burden: financial toxicity, which erodes savings and mental health, and time toxicity, the sheer number of hours spent in treatment and medical appointments. Patients experiencing financial toxicity reported meaningfully worse mental quality of life, while those experiencing time toxicity had worse physical functioning.26PubMed Central. Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma Patients who were dependent on transfusions, on dialysis, or who survived less than a year after diagnosis were more likely to enroll late in hospice and to receive aggressive medical care near the end of life, suggesting that the system often fails to transition patients to comfort-focused care in time.27PubMed Central. Quality of Life Meaningful changes in end-of-life care among patients with myeloma
Second Cancers as a Consequence of Longer Survival
One of the more unsettling developments as myeloma patients live longer is a growing awareness that certain treatments may increase the risk of developing a second, unrelated cancer. This is not a reason to avoid treatment, but it is a consequence of success that patients and doctors now have to manage. Lenalidomide, one of the backbone drugs used in maintenance therapy after transplant, has been consistently associated with a modest increase in second primary malignancies across multiple large trials. Meta-analyses suggest the risk of a second blood cancer is roughly two to four times higher with lenalidomide maintenance compared with observation, while the risk of a second solid-organ cancer is slightly elevated, in the range of one to two times higher.28PubMed Central. Second malignancies in multiple myeloma; emerging patterns and future directions
This trade-off is generally accepted because the survival benefit of lenalidomide maintenance far outweighs the added cancer risk for most patients. But it is a real consideration in long-term care planning, and as survival times continue to extend, the cumulative exposure to myeloma therapies means that monitoring for second cancers is becoming a routine part of follow-up.29PubMed Central. Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018 The irony is worth noting: the better we get at keeping myeloma patients alive, the more we have to watch for complications that arise precisely because they are living long enough for those complications to appear.
Racial Disparities in Access and Outcomes
Myeloma is roughly twice as common in Black populations as in White populations, and it tends to appear at younger ages. An analysis of FDA drug-approval trials found that Black patients enrolled in those trials actually had a slightly longer estimated median overall survival than White patients, at about 63 months versus about 48 months, though the difference was not statistically significant.30PubMed Central. Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials That finding is encouraging in one sense: when Black patients receive the same treatments in clinical trial settings, they do at least as well. But clinical trial populations do not reflect the real world. Disparities in access to newer drugs, to transplant centers, and to clinical trials themselves remain significant. The biology of myeloma may not discriminate by race, but the health care system does, and that can alter whether the disease behaves as a chronic illness or a rapidly fatal one for a given individual.